Form 4: Penumbra CEO Adam Elsesser Exercises Options and Sells Shares Under 10b5-1 Plan

Penumbra Inc.'s CEO and President, Adam Elsesser, executed a series of transactions on May 28, 2025, involving the exercise of stock options and subsequent sale of common stock to cover exercise costs and tax obligations.

Summary

• Adam Elsesser, CEO and President, and a Director of Penumbra Inc. (PEN), acquired 27,976 shares of common stock by exercising stock options at an exercise price of $30 per share on May 28, 2025.
• Concurrently, Mr. Elsesser sold a total of 16,300 shares of Penumbra common stock on May 28, 2025, through multiple trades at weighted average prices ranging from $263.42 to $273.40.
• These sales were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan, specifically to satisfy the exercise price and tax withholding obligations associated with the exercised stock options.
• Following these transactions, Mr. Elsesser's direct beneficial ownership of Penumbra common stock stands at 98,289 shares.
• Additionally, Mr. Elsesser indirectly beneficially owns 577,582 shares held by the Siegel/Elsesser Revocable Trust.
• He retains 195,836 unexercised stock options with an exercise price of $30, which are exercisable until September 16, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The document reports routine insider transactions (option exercise and subsequent sales for tax/exercise costs) conducted under a pre-arranged 10b5-1 plan, which is a standard practice for executives managing their equity compensation and does not typically indicate a change in company fundamentals or management's view of the company's prospects.

Positives

• The exercise of stock options indicates the vesting and exercisability of a significant number of shares, reflecting past performance and retention incentives for the CEO.
• The transactions were executed under a Rule 10b5-1 trading plan, which provides an affirmative defense against insider trading allegations, indicating pre-planned and transparent activity.

Negatives

• The sale of 16,300 shares by a key executive, even if for tax and exercise purposes, represents a reduction in direct ownership, which some investors might view as a slight negative, though it is a common practice.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Management Comments

• The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
• The Reporting Person entered into the Rule 10b5-1 trading plan in connection with the expiration of certain stock options held by the Reporting Person and related sales of shares to satisfy the exercise price and tax withholding obligations upon the exercise of such stock options.

Industry Context

This filing pertains to an individual insider transaction and does not provide information directly related to broader industry trends or competitive landscape within the medical device sector. Such transactions are common for executives managing their equity compensation.

Related Party Transactions

• 577,582 shares are held indirectly by the Siegel/Elsesser Revocable Trust, indicating a related party holding.

Stakeholder Impact

• Shareholders: The transaction is a routine insider sale for tax and exercise purposes, unlikely to have a significant direct impact on shareholder value or perception beyond standard executive compensation management.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Keywords

Penumbra Inc., PEN, Adam Elsesser, CEO, Insider Trading, Form 4, Stock Options, Rule 10b5-1 Plan, Share Sale, Beneficial Ownership, Medical Devices